Natco launches blood cancer drug pomalidomide in India

Natco will market generic pomalidomide capsules under its brand name POMALID in India. Natco priced its generic medicine of POMALID 1 mg, 2 mg, and 4 mg capsules at an Rs.5000, Rs.10,000, and Rs.20,000 respectively for a monthly pack of 21 capsules.
Natco Pharma on Wednesday said it has launched a generic version of blood cancer drug pomalidomide in India.
The drug which is sold under brand name Pomalyst by Celegene in the US.
Natco will market generic pomalidomide capsules under its brand name POMALID in India. The generic medicine will be available in three dosages of 1 mg, 2 mg, and 4 mg capsules, priced at Rs 5000, Rs 10,000, and Rs.20,000 respectively for a monthly pack of 21 capsules.
Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
"We believe, this is approximately 98 percent discount of price from what it is sold at in the USA to patients, per secondary market data researched," Natco claimed.
The latest drug is expected to strengthen Natco's oncology portfolio. Natco derives around one-third of its revenues from oncology. The oncology division was major revenue generator for Natco before it was eclipsed by its hepatitis-C franchisee in FY16. Natco revenues stood at Rs 1152.8 crore in FY16. Oncology portfolio of Natco has grown 30 percent in FY16.
Shares of Natco rose 0.07 percent to close at Rs 896 on BSE, the benchmark Sensex gained 1.05 percent to 30,248.17 points.

Source:http://www.moneycontrol.com/news/business/companies/natco-launches-blood-cancer-drug-pomalidomide-in-india-2275711.html

Comments

Post a Comment

Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product ramucirumab (Cyramza). The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. The CHMP adopted a new indication as follows: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib”. For information, the full indications for Cyramza will be as follows : Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatm
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first three pillars. Fred
Read more

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer

Merck announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant phase 3 study KEYNOTE-522. The trial investigated neoadjuvant Keytruda, Merck’s anti-PD-1 therapy, plus chemotherapy followed by adjuvant Keytruda as monotherapy (the Keytruda regimen) compared with neoadjuvant chemotherapy followed by adjuvant placebo (the chemotherapy-placebo regimen) in patients with high-risk early-stage triple-negative breast cancer (TNBC). This is the first time an anti-PD-1/L1 therapy has demonstrated a statistically significant EFS result as combined neoadjuvant and adjuvant therapy for these patients. These results are being presented today during a European Society for Medical Oncology (ESMO) Virtual Plenary. After a median follow-up of 39 months, the Keytruda regimen reduced the risk of EFS events by 37% (HR=0.63 [95% CI, 0.48-0.82]; p=0.00031) versus the chemotherapy-placebo regimen – a statistically significant and clinically meaningful EFS result. EFS was defined
Read more